A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis

Exclusion Criteria

• •Predominantly palmo-plantar, flexural, scalp and nail location of psoriasis
• •Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis.
• •Patient with any uncontrolled systemic disease
• •Patient with positive serology tests like HIV, HCV \& HBsAg.
• •Patient with presence of any skin disease that might interfere with the diagnosis or evaluation of the test medications.
• •Patient with spontaneously improving or rapidly deteriorating plaque psoriasis.
• •Use of systemic agents within four weeks prior to screening.
• •Use of biologic agents within four weeks prior to study entry.
• •Use of topical drugs that might alter the course of psoriasis or has received ultraviolet B treatment within two weeks prior to study entry.
• •Use of phototherapy with psoralen ultraviolet A treatment within four weeks prior to study entry.
• •Known sensitivity to any of the study treatments and/or study treatment's components.
• •Need for surgery or hospitalization during the study
• •Pregnant or nursing Female patient or planning a pregnancy
• •Concurrent involvement in any other clinical study within 30 days prior to entering the study